Acetyl Hexapeptide-51 | CAS:NO15

We serve Acetyl Hexapeptide-51 CAS:NO15 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Acetyl Hexapeptide-51

Chemical Name:Acetyl Hexapeptide-51
CAS.NO:NA
Synonyms:Acetyl Hexapeptide-51
Juveleven
Juvefoxo
 
Physical and Chemical Properties:
Molecular Formula C17H27N7O5
Molecular Weight 409.44
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:5 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Acetyl-hexapeptide-51 can prevent direct or indirect damage of ultraviolet rays to DNA and skin proteins, thereby preventing photoaging.



Contact us for information like Acetyl Hexapeptide-51 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Juvefoxo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acetyl Hexapeptide-51 Use and application,Acetyl Hexapeptide-51 technical grade,usp/ep/jp grade.


Related News: With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.3-Hydroxy-4-methoxybenzonitrile manufacturer The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.2-thioladenosine supplier The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.2-Chloro-3-Fluoro-6-Picoline vendor The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion.The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth.